Related Experiment Video
Updated: Aug 7, 2026
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
DNMT3A Co-Mutation and Real-World Clinical Outcomes With Gilteritinib in FLT3-Mutated Acute Myeloid Leukaemia Across
Francesca Duca1,2, Beatrice Manghisi2, Andrea Palasciano3,4
1Department of Medicine and Surgery University of Milano-Bicocca Monza Italy.
Introduction:
Molecular co-mutations modulate outcomes in FLT3-mutated AML treated with gilteritinib; real-world data stratified by DNMT3A co-mutation status are lacking.
Methods:
We retrospectively analysed 29 adults with R/R FLT3-mutated AML treated at two Italian centres. Sixteen patients with complete molecular profiling were stratified into three subgroups by DNMT3A and NPM1 co-mutation status.
Results:
Overall response rate was 89.7% (26/29). DNMT3A-mutated subgroups showed prolonged OS from gilteritinib initiation versus wild-type group (median not reached vs. 8.8 months; 12-month OS 78% vs. 17%).
Conclusions:
These hypothesis-generating data suggest that DNMT3A co-mutation status is associated with differential gilteritinib outcomes, supporting comprehensive molecular profiling in FLT3-mutated AML.
Trial Registration:
The authors have confirmed clinical trial registration is not needed for this submission.
